The recently approved FDA Modernization Act allows drug manufacturers to replace poorly predictive preclinical animal tests with modern testing methods.
According to Tessara Therapeutics many animal models don’t work well and misrepresent human physiology, especially the brain.
Already, in several countries, including Australia, Dementia and Alzheimer’s is among the leading causes of death. Hence, there is an urgent demand for new, human-relevant models enabling accurate selection of drugs entering the development pipeline.
Tessara’s Drug Screening Platform reflects human neurophysiology and is reproducible at scale for use in the pharmaceutical industry, enabling the discovery and development of novel therapeutic candidates to treat neurological diseases, including Alzheimers Disease.